Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 11:23 PM ET


Company Overview of Tamir Biotechnology, Inc.

Company Overview

Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...

12625 High Bluff Drive

Suite 113

San Diego, CA 92130

United States

Founded in 1981





Key Executives for Tamir Biotechnology, Inc.

Chief Executive Officer, President, Secretary, and Director
Age: 49
Chief Financial Officer and Secretary
Age: 53
Chairman of the Thoracic Cancer Advisory Board
Special Advisor to Chief Executive Officer
Age: 73
Compensation as of Fiscal Year 2015.

Tamir Biotechnology, Inc. Key Developments

Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola

Tamir Biotechnology announced an update on its Ebola antiviral therapy program. One of Tamir's candidates, TMR004, is currently being evaluated and considered by a number of clinicians on the frontline of the battle against Ebola. The company also this week received additional data from its continued investigation into the anti-Ebola properties of TMR004. In a therapeutic pre-clinical mouse model conducted at the University of Texas Medical Branch, the drug was administered intraperitoneally at three dose levels to animals previously infected with the Ebola virus. TMR004 conferred a statistically definitive survival advantage relative to the control group. This finding was consistent with earlier investigations in which the US Army Medical Research Institute for Infectious Diseases showed that prophylactically administered TMR004 confers one of the high survival rates observed for experimental drugs in the fight against Ebola virus. More studies are planned for the immediate future in additional animal models of infection. TMR004, the company's candidate, has a rich legacy as a therapeutic agent. This type III RNase is able to inhibit viral replication through halting synthesis of viral protein without altering cellular constituents. It is noteworthy that since TMR004 degrades double stranded RNA produced by most viruses, it less likely that viruses will develop resistance despite the high mutation rates seen with pathogens like Ebola. A form of the drug, formerly known by the ONCONASE trademark and as "Onconase for injection", was previously evaluated by the US Food and Drug Administration for over twenty years in numerous clinical trials. Its safety was considered sufficient to permit administration to over 1,000 patients as part of its development against malignant mesothelioma.

Similar Private Companies By Industry

Company Name Region
GenTrac, Inc. United States
Theragen LLC United States
Integenx Acquisition Corp. United States
AndroBioSys, Inc. United States
Arcion Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
September 4, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tamir Biotechnology, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at